Antiandrogens
Aspirin
Bromhexine
Budesonide
Cannabidiol
Casirivimab/i..
Colchicine
Conv. Plasma
Curcumin
Diet
Ensovibep
Exercise
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Melatonin
Metformin
Molnupiravir
Nigella Sativa
Nitazoxanide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Proxalutamide
Quercetin
Remdesivir
Sleep
Sotrovimab
Vitamin A
Vitamin C
Vitamin D
Zinc

Other
Feedback Home
Home   COVID-19 treatment studies for Ivermectin  COVID-19 treatment studies for Ivermectin  C19 studies: Ivermectin  Ivermectin   Select treatmentSelect treatmentTreatmentsTreatments
Antiandrogens (meta) Lactoferrin (meta)
Aspirin (meta) Melatonin (meta)
Bamlaniv../e.. (meta) Metformin (meta)
Bebtelovimab (meta) Molnupiravir (meta)
Bromhexine (meta) N-acetylcys.. (meta)
Budesonide (meta) Nigella Sativa (meta)
Cannabidiol (meta) Nitazoxanide (meta)
Casirivimab/i.. (meta) Paxlovid (meta)
Colchicine (meta) Peg.. Lambda (meta)
Conv. Plasma (meta) Povidone-Iod.. (meta)
Curcumin (meta) Probiotics (meta)
Diet (meta) Proxalutamide (meta)
Ensitrelvir (meta) Quercetin (meta)
Ensovibep (meta) Remdesivir (meta)
Exercise (meta) Sleep (meta)
Famotidine (meta) Sotrovimab (meta)
Favipiravir (meta) Tixagev../c.. (meta)
Fluvoxamine (meta) Vitamin A (meta)
Hydroxychlor.. (meta) Vitamin C (meta)
Iota-carragee.. (meta) Vitamin D (meta)
Ivermectin (meta) Zinc (meta)

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent: 
0 0.5 1 1.5 2+ Mortality 87% Improvement Relative Risk ICU admission 89% Progression 83% Recovery 87% Hospitalization time 40% Time to viral- 73% c19ivermectin.com Khan et al. Ivermectin for COVID-19 LATE TREATMENT Favors ivermectin Favors control
Khan, 248 patient ivermectin late treatment study: 87% lower mortality [p=0.02], 89% lower ICU admission [p=0.007], 83% lower progression [p=0.0004], and 87% improved recovery [p=0.02] https://c19p.org/khan
copied to clipboard
Ivermectin treatment may improve the prognosis of patients with COVID-19
Khan et al., Archivos de Bronconeumología, doi:10.1016/j.arbres.2020.08.007 (Letter)
24 Sep 2020    Source   PDF   Share   Tweet
Retrospective 115 ivermectin patients and 133 control patients showing significantly lower death and faster viral clearance. Some potential issues and the authors' response can be found in [sciencedirect.com, sciencedirect.com (B)].
risk of death, 87.1% lower, RR 0.13, p = 0.02, treatment 1 of 115 (0.9%), control 9 of 133 (6.8%), NNT 17.
risk of ICU admission, 89.5% lower, RR 0.11, p = 0.007, treatment 1 of 115 (0.9%), control 11 of 133 (8.3%), NNT 14.
risk of progression, 83.5% lower, RR 0.17, p < 0.001, treatment 3 of 115 (2.6%), control 21 of 133 (15.8%), NNT 7.6.
risk of no recovery, 87.1% lower, RR 0.13, p = 0.02, treatment 1 of 115 (0.9%), control 9 of 133 (6.8%), NNT 17.
hospitalization time, 40.0% lower, relative time 0.60, p < 0.001, treatment 115, control 133.
time to viral-, 73.3% lower, relative time 0.27, p < 0.001, treatment 115, control 133.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Khan et al., 9/24/2020, retrospective, Bangladesh, South Asia, preprint, median age 35.0, 8 authors, dosage 12mg single dose.
All Studies   Meta Analysis
This PaperIvermectinAll
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and treatments are both valuable and complementary. All practical, effective, and safe means should be used. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. Denying the efficacy of any method increases mortality, morbidity, collateral damage, and the risk of endemic status. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit